X4 Pharmaceuticals (XFOR) Earnings Date, Estimates & Call Transcripts $0.64 -0.02 (-2.50%) (As of 10:07 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Earnings SummaryUpcoming Earnings DateNov. 14EstimatedActual EPS (Aug. 8) -$0.07 Missed By -$0.03 Consensus EPS (Aug. 8) -$0.04 Conference Call TranscriptConference Call AudioEarnings Press Release Get X4 Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for XFOR and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueXFOR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.XFOR Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilson, an extremely rare window in the markets is about to open. It's an often-misunderstood market setup we've only seen 13 times since 1920. The last time this happened, it minted a million brand-new millionaires – in a single year. But Tilson says this unique window in the markets could close much sooner than anyone realizes, leaving most investors in the dust, while making a select few incredibly rich.Get our No. 1 stock (with 500%-plus upside potential) for this rare market event now. X4 Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243($0.22)($0.14)($0.18)Q2 20244($0.24)($0.18)($0.20)Q3 20244($0.18)($0.17)($0.17)Q4 20244($0.17)($0.13)($0.15)FY 202415($0.81)($0.62)($0.70)Q1 20251($0.13)($0.13)($0.13)Q2 20251($0.12)($0.12)($0.12)Q3 20251($0.08)($0.08)($0.08)Q4 20251($0.05)($0.05)($0.05)FY 20254($0.38)($0.38)($0.38)XFOR Earnings Date and InformationX4 Pharmaceuticals last issued its earnings data on August 8th, 2024. The reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.03. The company earned $0.56 million during the quarter, compared to analyst estimates of $52.98 million. X4 Pharmaceuticals has generated ($0.70) earnings per share over the last year (($0.70) diluted earnings per share). Earnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.65) to ($0.45) per share. X4 Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off prior year's report dates.Read More X4 Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/14/2024(Estimated)------- 8/8/2024Q2 2024($0.04)($0.07)($0.03)($0.59)$52.98 million$0.56 million 5/7/2024Q1 2024($0.17)($0.26)($0.09)($0.26)-- 3/21/2024Q4 2023($0.15)($0.10)+$0.05($0.10)-- 11/9/2023Q3 2023($0.15)($0.01)+$0.14($0.01)-- 8/10/2023Q2 2023($0.17)($0.33)($0.16)($0.33)-- 5/4/2023Q1 2023($0.20)($0.16)+$0.04($0.16)-- Get the Latest News and Ratings for XFOR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 3/21/2023Q4 2022($0.23)($0.29)($0.06)($0.29)-- 11/3/2022Q3 2022($0.31)($0.26)+$0.05($0.26)-- 8/4/2022Q2 2022($0.65)($0.60)+$0.05($0.60)-- 5/12/2022Q1 2022($0.62)($0.72)($0.10)($0.72)-- 3/17/2022Q4 2021($0.68)($1.24)($0.56)($1.24)-- 11/4/2021Q3 2021($0.72)($0.76)($0.04)($0.76)-- 8/3/2021Q2 2021($0.73)($0.74)($0.01)($0.74)-- 5/6/2021Q1 2021($0.84)($1.30)($0.46)($1.30)-- 3/4/2021Q4 2020($0.87)($0.91)($0.04)($0.91)-- 11/5/2020Q3 2020($0.74)($0.87)($0.13)($0.87)--7/30/2020Q2 2020($0.70)($0.76)($0.06)($0.76)-- 5/7/2020Q1 2020($0.83)($0.56)+$0.27($0.56)-$3.00 million 3/12/2020Q4 2019($0.83)($0.66)+$0.17($0.66)-- 11/7/2019Q3 2019($0.95)($0.95)-($0.68)-- X4 Pharmaceuticals Earnings - Frequently Asked Questions When is X4 Pharmaceuticals's earnings date? X4 Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates. Learn more on XFOR's earnings history. Did X4 Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, X4 Pharmaceuticals (NASDAQ:XFOR) missed the analysts' consensus estimate of ($0.04) by $0.03 with a reported earnings per share (EPS) of ($0.07). Learn more on analysts' earnings estimate vs. XFOR's actual earnings. How can I listen to X4 Pharmaceuticals's earnings conference call? The conference call for X4 Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read X4 Pharmaceuticals's conference call transcript? The conference call transcript for X4 Pharmaceuticals's latest earnings report can be read online. Read Transcript How much profit does X4 Pharmaceuticals generate each year? X4 Pharmaceuticals (NASDAQ:XFOR) has a recorded net income of -$101.17 million. XFOR has generated -$0.70 earnings per share over the last four quarters. What is X4 Pharmaceuticals's EPS forecast for next year? X4 Pharmaceuticals's earnings are expected to grow from ($0.65) per share to ($0.45) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Cidara Therapeutics Earnings Results Curis Earnings Results Contineum Therapeutics Earnings Results Larimar Therapeutics Earnings Results Foghorn Therapeutics Earnings Results Canopy Growth Earnings Results Cryoport Earnings Results Neurogene Earnings Results Taysha Gene Therapies Earnings Results C4 Therapeutics Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Is Merck Stock Undervalued After Its Colossal Earnings Growth?Polestar Lives to Fight Another Day After Q2 EarningsWhy NVIDIA’s Earnings Point to a Bullish Future for Pure StorageDoes A&F's Q2 Earnings Win Point to a Strong Holiday Season?Salesforce Beats Earnings, Raises Full-Year Profit OutlookDon’t Count Out CrowdStrike Yet: Key Insights from Q2 EarningsNVIDIA: Analysts Bullish Ahead of Earnings - Is It a Buy Now? This page (NASDAQ:XFOR) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
